Table 1 Changes in demographic and clinical characteristics over 5-year
|  | Baseline (n = 60) | 5 years (n = 60) | Change (n = 60) | P value |
|---|---|---|---|---|
Demographic characteristics | ||||
 Female, N (%) | 27 (45.0) |  |  |  |
 Smokers, N (%) | 13 (21.7) |  |  |  |
 Age, year | 51.9 ± 8.9 |  |  |  |
 BMI | 25.4 ± 4.3 | 25.8 ± 4.5 | 0.46 ± 1.9 | 0.060 |
 Height (cm) | 163.6 ± 8.5 | 163.0 ± 8.4 | −0.57 ± 1.3 | 0.002 |
 Weight (kg) | 68.2 ± 14.3 | 68.8 ± 14.0 | 0.62 ± 5.1 | 0.345 |
Disease-specific characteristics | ||||
 Duration of psoriasis (year) | 18.7 ± 16.7 | |||
 Duration of PsA (year) | 14.3 ± 6.9 | |||
 Juxta-articular new bone formation | 29 (48.3) | |||
 Polyarticular | 21 (35.0) | |||
 Oligoarticular | 17 (28.3) | |||
 Presence of enthesitis | 13 (21.7) | |||
 Presence of dactylitis | 8 (13.3) | |||
 Tender joint at MCP2 | 8 (13.3) | |||
 Tender joint at MCP3 | 4 (6.6) | |||
 Swollen joint at MCP2 | 3 (5.0) | |||
 Swollen joint at MCP3 | 2 (3.3) | |||
 CRP (mg/L) | 4.4 ± 4.9 | 4.0 ± 5.2 | −0.4 ± 5.7 | 0.629 |
 ESR (mm/h) | 19.0 ± 15.9 | 27.5 ± 17.4 | 8.7 ± 13.3 | 0.000 |
 DAPSA | 11.4 ± 9.3 | 9.7 ± 5.9 | −1.7 ± 9.0 | 0.150 |
 PASI | 6.3 ± 8.6 | 4.7 ± 6.4 | −1.6 ± 7.2 | 0.088 |
 HAQ | 0.3 ± 0.4 | 0.4 ± 0.5 | 0.1 ± 0.4 | 0.067 |
 MASES | 0.9 ± 2.4 | 0.5 ± 1.4 | −0.5 ± 1.8 | 0.035 |
 VAS pain (mm) | 31.1 ± 26.1 | 31.1 ± 24.5 | 0 ± 26.4 | 1.000 |
 VAS PhyGA (mm) | 23.8 ± 18.9 | 18.5 ± 18.2 | −5.4 ± 21.8 | 0.060 |
 VAS PatGA (mm) | 41.0 ± 28.3 | 37.0 ± 22.9 | −4.0 ± 26.0 | 0.243 |
 Tender joint count | 2.9 ± 5.7 | 1.8 ± 2.8 | −1.2 ± 5.4 | 0.103 |
 Swollen joint count | 0.8 ± 1.5 | 0.7 ± 1.6 | −0.1 ± 1.7 | 0.597 |
 Deformed joint count | 3.8 ± 6.4 | 7.0 ± 7.4 | 3.2 ± 5.5 | 0.000 |
Current/ever treatment | ||||
 NSAIDs, N (%) | 25 (41.7) | 28 (46.7) |  | 0.080 |
 Corticosteroids, N (%) | 3 (5.0) | 4 (6.7) | 1.000 | |
 csDMARDs, N (%) | 44 (73.3) | 49 (81.7) | 0.274 | |
 bDMARDs, N (%) | 16 (26.7) | 23 (35.3) | 0.172 | |
 Any DMARDs, N (%) | 46 (76.7) | 53 (88.3) | 0.093 | |
 csDMARDs + bDMARDs, N (%) | 16 (26.7) | 19 (31.7) | 0.547 | |
Clinical response | ||||
 VLDA, N (%) | 4 (6.7) | 8 (13.3) |  | 0.083 |
 MDA, N (%) | 15 (25.0) | 22 (36.7) | 0.166 | |
 REM (DAPSA ≤4), N (%) | 14 (23.3) | 13 (21.7) | 0.044 | |
 LDA (DAPSA ≤14), N (%) | 26 (43.3) | 29 (48.3) | ||
 MDA (DAPSA ≤28), N (%) | 17 (28.3) | 18 (30.0) | ||
 HDA (DAPSA >28), N (%) | 3 (5.0) | 0 (0) | ||